Exclusive Interview with VGOD: Once the Top E-Liquid Brand in US, Set to Relaunch in Malaysia

2Firsts Events by 2FIRSTS
Sep.06.2024
Exclusive Interview with VGOD: Once the Top E-Liquid Brand in US, Set to Relaunch in Malaysia
ANTY EXPO opens in Malaysia; VGOD discusses market challenges and re-entry strategy at international tobacco industry exhibition.

On September 6, the Asian International New Tobacco Industry Expo (ANTY EXPO) officially opened at the Malaysia International Exhibition and Convention Centre (MIECC). At the exhibition, 2Firsts invited VGOD's Director of Marketing, Kenny, to discuss VGOD's position in the American market, strategies for dealing with policy changes, as well as their plans for re-entering the Malaysian market and future plans.

 

Challenges and Opportunities for VGOD in the American Market

 

VGOD was once one of the leading brands in the American e-cigarette market, with its self-developed e-liquid brand ranking as the top in the market at one point. However, with the increasing regulatory efforts by the FDA in the e-cigarette market, VGOD is facing more pressure. Currently, VGOD's e-liquid brand remains in the top 5 in the American market. Kenny admitted, "The FDA's regulatory policies are constantly changing, and at the same time, the e-cigarette regulations vary from state to state in the United States, adding complexity to market compliance.

 

Faced with tightening regulations, VGOD is actively adjusting its strategies to ensure its continued presence and competitiveness in the US market. At the same time, VGOD has also achieved good results outside the US market. Kenny revealed to two sources that VGOD is currently ranked top 1 in the Middle East market, marking an important step towards internationalization.

 

Exclusive Interview with VGOD: Once the Top E-Liquid Brand in US, Set to Relaunch in Malaysia
VGOD booth | Image source: 2Firsts

 

Abandoning and Returning: VGOD's Market Strategy in Malaysia

 

When discussing the Malaysian market, Kenny pointed out that VGOD once focused primarily on the high vapor market in Malaysia and gained a certain market share. However, with the rise of disposable e-cigarette products, consumer preferences changed significantly, leading VGOD to choose to exit the Malaysian market at that time.

 

In recent years, with the further development of the e-cigarette market in Malaysia and changes in consumer preferences, VGOD has reassessed the potential of this market. Kenny stated:

 

The consumer structure in the Malaysian market is undergoing a transformation. Based on this trend, VGOD is determined to re-enter the Malaysian market and reorganize our product line.

 

Expand business operations in Southeast Asia market

 

In the face of the complex international market situation, VGOD is undergoing global strategic adjustments, especially in response to changing market demands in different regions, by introducing more flavors of products. Kenny revealed that their participation in the exhibition in Malaysia signifies VGOD's continuous expansion in Malaysia and other emerging markets in Southeast Asia. "We hope to meet the diverse needs of global consumers through technological innovation and high-quality product experiences." VGOD is accelerating its internationalization and looks forward to continuing to play a leading role in the global e-cigarette market.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How are investors reassessing the global tobacco industry as nicotine markets evolve? In an interview with 2Firsts, Charlie Chen, Head of Research at CCB International Securities, forecasts annual growth of 30–50% for nicotine pouches, outpacing vaping and heated tobacco. He examines how regulatory enforcement, shifting market shares and new business models are influencing company valuations. The report also explores differences between multinational tobacco groups and Chinese companies, drawing on insights from the New Approaches Summit on profitability, investment strategies and industry consolidation.
Nov.11
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's regional vape retail restrictions are expanding. State Duma Speaker Vyacheslav Volodin said on November 7 that 17 regions had adopted decisions to ban vape sales, while another 39 were preparing or considering similar legislation. On November 12, lawmakers in Leningrad Oblast and the Republic of Karelia adopted bans scheduled to begin on March 1, 2027. A day earlier, St. Petersburg unanimously approved a five-year ban proposal in its first reading. The city has 615 specialist vape shops and more than 2,400 other retail outlets selling vaping products alongside other goods. Under Federal Law No. 186-FZ, enacted in June 2026, Russian regions may prohibit retail sales of electronic nicotine delivery systems and related liquids between March 2027 and March 2032. The legislation also restricts licensed suppliers from delivering covered products to retail premises in regions where bans apply.
Regulations
Nov.13
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07